» Articles » PMID: 36577076

The Direct Binding of AMA1 to Erythrocytes Defines a RON2-independent Invasion Pathway

Abstract

We used a transgenic parasite in which parasites were genetically modified to express apical membrane antigen 1 (PvAMA1) protein in place of PfAMA1 to study PvAMA1-mediated invasion. In , AMA1 interaction with rhoptry neck protein 2 (RON2) is known to be crucial for invasion, and PfRON2 peptides (PfRON2p) blocked the invasion of PfAMA1 wild-type parasites. However, PfRON2p has no effect on the invasion of transgenic parasites expressing PvAMA1 indicating that PfRON2 had no role in the invasion of PvAMA1 transgenic parasites. Interestingly, PvRON2p blocked the invasion of PvAMA1 transgenic parasites in a dose-dependent manner. We found that recombinant PvAMA1 domains 1 and 2 (rPvAMA1) bound to reticulocytes and normocytes indicating that PvAMA1 directly interacts with erythrocytes during the invasion, and invasion blocking of PvRON2p may result from it interfering with PvAMA1 binding to erythrocytes. It was previously shown that the peptide containing Loop1a of PvAMA1 (PvAMA1 Loop1a) is also bound to reticulocytes. We found that the Loop1a peptide blocked the binding of PvAMA1 to erythrocytes. PvAMA1 Loop1a has no polymorphisms in contrast to other PvAMA1 loops and may be an attractive vaccine target. We thus present the evidence that PvAMA1 binds to erythrocytes in addition to interacting with PvRON2 suggesting that the merozoites may exploit complex pathways during the invasion process.

Citing Articles

Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages.

Winnicki A, Dietrich M, Yeoh L, Carias L, Roobsoong W, Drago C Nat Commun. 2024; 15(1):10556.

PMID: 39632799 PMC: 11618605. DOI: 10.1038/s41467-024-53848-4.


A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites.

Angage D, Chmielewski J, Maddumage J, Hesping E, Caiazzo S, Lai K Nat Commun. 2024; 15(1):7206.

PMID: 39174515 PMC: 11341838. DOI: 10.1038/s41467-024-50770-7.


Complement receptor 1 is the human erythrocyte receptor for erythrocyte binding protein.

Lee S, Crosnier C, Valenzuela-Leon P, Dizon B, Atkinson J, Mu J Proc Natl Acad Sci U S A. 2024; 121(5):e2316304121.

PMID: 38261617 PMC: 10835065. DOI: 10.1073/pnas.2316304121.


Comparative analysis of codon usage patterns of helical interspersed subtelomeric (PHIST) proteins.

Yang B, Cheng Z, Luo L, Cheng K, Gan S, Shi Y Front Microbiol. 2023; 14:1320060.

PMID: 38156001 PMC: 10752978. DOI: 10.3389/fmicb.2023.1320060.


Unveiling P. vivax invasion pathways in Duffy-negative individuals.

Bouyssou I, El Hoss S, Doderer-Lang C, Schoenhals M, Rasoloharimanana L, Vigan-Womas I Cell Host Microbe. 2023; 31(12):2080-2092.e5.

PMID: 38056460 PMC: 10727064. DOI: 10.1016/j.chom.2023.11.007.


References
1.
Smith L, Duge E, Valenzuela-Leon P, Brooks S, Martin-Martin I, Ackerman H . Novel salivary antihemostatic activities of long-form D7 proteins from the malaria vector Anopheles gambiae facilitate hematophagy. J Biol Chem. 2022; 298(6):101971. PMC: 9123270. DOI: 10.1016/j.jbc.2022.101971. View

2.
MILLER L, Mason S, DVORAK J, McGinniss M, Rothman I . Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science. 1975; 189(4202):561-3. DOI: 10.1126/science.1145213. View

3.
Lamarque M, Besteiro S, Papoin J, Roques M, Vulliez-Le Normand B, Morlon-Guyot J . The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog. 2011; 7(2):e1001276. PMC: 3037350. DOI: 10.1371/journal.ppat.1001276. View

4.
Ntumngia F, Thomson-Luque R, Torres L, Gunalan K, Carvalho L, Adams J . A Novel Erythrocyte Binding Protein of Plasmodium vivax Suggests an Alternate Invasion Pathway into Duffy-Positive Reticulocytes. mBio. 2016; 7(4). PMC: 4999553. DOI: 10.1128/mBio.01261-16. View

5.
Drew D, Wilson D, Elliott S, Cross N, Terheggen U, Hodder A . A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens. BMC Med. 2016; 14(1):144. PMC: 5034621. DOI: 10.1186/s12916-016-0691-6. View